Trends in use of contralateral prophylactic mastectomy by racial/ethnic group and ER/PR status among patients with breast cancer: A SEER population-based study

Cancer Epidemiology

Volumn 42, Issue , 2016, Pages 24-31

  Brown, Derek ^a   Shao, Stephanie ^a,b   Jatoi, Ismail ^c   Shriver, Craig D ^a,b   Zhu, Kangmin ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Contralateral prophylactic mastectomy; Ethnicity; Hormone receptor; Race; SEER

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROGESTERONE;

ADULT; AGED; ARTICLE; ASIAN; BLACK PERSON; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CAUCASIAN; CONTRALATERAL PROPHYLACTIC MASTECTOMY; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HISPANIC; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; PACIFIC ISLANDER; PRIORITY JOURNAL; RACE DIFFERENCE; BREAST NEOPLASMS; ETHNOLOGY; METABOLISM; MIDDLE AGED; PROPHYLACTIC MASTECTOMY; TRENDS; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; ETHNIC GROUPS; FEMALE; HUMANS; MIDDLE AGED; PROGESTERONE; PROPHYLACTIC MASTECTOMY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 84961151908     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.02.011     Document Type: Article

References (31)

1. Nichols H.B., Berrington de Gonzalez A., Lacey J.V., Rosenberg P.S., Anderson W.F. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J. Clin. Oncol. 2011, 29(12):1564-1569. 10.1200/jco.2010.32.7395.
2. Chen Y., Thompson W., Semenciw R., Mao Y. Epidemiology of contralateral breast cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. Am. Soc. Prev. Oncol. 1999, 8(10):855-861.
3. Surgery to Reduce the Risk of Breast Cancer, (2013) 2015. http://www.cancer.gov/cancertopics/factsheet/Therapy/risk-reducing-surgery.
4. Tuttle T.M., Habermann E.B., Grund E.H., Morris T.J., Virnig B.A. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J. Clin. Oncol. 2007, 25(33):5203-5209. 10.1200/JCO.2007.12.3141.
5. Yao K., Stewart A.K., Winchester D.J., Winchester D.P. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann. Surg. Oncol. 2010, 17(10):2554-2562. 10.1245/s10434-010-1091-3.
6. Healey E.A., Cook E.F., Orav E.J., Schnitt S.J., Connolly J.L., Harris J.R. Contralateral breast cancer: clinical characteristics and impact on prognosis. J. Clin. Oncol. 1993, 11(8):1545-1552.
7. Portschy P.R., Kuntz K.M., Tuttle T.M. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J. Natl. Cancer Inst. 2014, 106(8). 10.1093/jnci/dju160.
8. Habermann E.B., Abbott A., Parsons H.M., Virnig B.A., Al-Refaie W.B., Tuttle T.M. Are mastectomy rates really increasing in the United States?. J. Clin. Oncol. 2010, 28(21):3437-3441. 10.1200/jco.2009.27.6774.
9. Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A., Aguilar M., Marubini E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 2002, 347(16):1227-1232. 10.1056/NEJMoa020989.
10. Jones N.B., Wilson J., Kotur L., Stephens J., Farrar W.B., Agnese D.M. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann. Surg. Oncol. 2009, 16(10):2691-2696. 10.1245/s10434-009-0547-9.
11. McLaughlin C.C., Lillquist P.P., Edge S.B. Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005. Cancer 2009, 115(23):5404-5412. 10.1002/cncr.24623.
12. Tuttle T.M., Jarosek S., Habermann E.B., Arrington A., Abraham A., Morris T.J., Virnig B.A. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J. Clin. Oncol. 2009, 27(9):1362-1367. 10.1200/JCO.2008.20.1681.
13. Yakoub D., Avisar E., Koru-Sengul T., Miao F., Tannenbaum S.L., Byrne M.M., Moffat F., Livingstone A., Franceschi D. Factors associated with contralateral preventive mastectomy. Breast Cancer 2015, 7:1-8. 10.2147/BCTT.S72737.
14. Britton J.A., Gammon M.D., Schoenberg J.B., Stanford J.L., Coates R.J., Swanson C.A., Potischman N., Malone K.E., Brogan D.J., Daling J.R., Brinton L.A. Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. Am. J. Epidemiol. 2002, 156(6):507-516.
15. Dunnwald L.K., Rossing M.A., Li C.I. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9(1):R6. 10.1186/bcr1639.
16. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet 351 (9114) (1998) 1451-1467.
17. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361(9354):296-300. 10.1016/S0140-6736(03)12342-2.
18. Komen S.G. Tumor Characteristics 2013, http://ww5.komen.org/BreastCancer/TumorCharacteristics.html.
19. Network NCC NCCN Clinical Practice Guidelines in Oncology: Breast Cancer 2014, http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
20. Saltzman B.S., Malone K.E., McDougall J.A., Daling J.R., Li C.I. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res. Treat. 2012, 135(3):849-855. 10.1007/s10549-012-2183-5.
21. Surveillance E, and End Results Program Overview of the SEER Program. http://seer.cancer.gov/about/overview.html.
22. Surveillance E, and End Results Program, SEER Program Coding and Staging Manual 2014. (2014). http://seer.cancer.gov/manuals/2014/AppendixC/breast/surgery_codes.pdf.
23. Cancer AJCo, AJCC Cancer Staging Manual Sixth Edition (2002).
24. Surveillance E, and End Results Program Code for Histologic Grading and Differentiation. http://training.seer.cancer.gov/coding/guidelines/rule_g.html.
25. Agarwal S., Kelley Kidwell, Kraft Casey T., Kozlow Jeffrey H., Michael Sabel, Chung Kevin C., Momoh Adeyiza O. A rising trend in use of contralateral prophylactic mastectomy: does the decision to undergo immediate reconstruction play a role?. Plastic Reconstructive Surg. 2014, 134(4S-1):87.
26. Shippee T.P., Kozhimannil K.B., Rowan K., Virnig B.A. Health insurance coverage and racial disparities in breast reconstruction after mastectomy. Womens Health Issues 2014, 24(3):e261-e269. 10.1016/j.whi.2014.03.001.
27. Huang W.Y., Newman B., Millikan R.C., Schell M.J., Hulka B.S., Moorman P.G. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am. J. Epidemiol. 2000, 151(7):703-714.
28. Elledge R.M., Clark G.M., Chamness G.C., Osborne C.K. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J. Natl. Cancer Inst. 1994, 86(9):705-712.
29. Baquet C.R., Mishra S.I., Commiskey P., Ellison G.L., DeShields M. Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. J. Natl. Med. Assoc. 2008, 100(5):480-488.
30. Arpino G., Weiss H., Lee A.V., Schiff R., De Placido S., Osborne C.K., Elledge R.M. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl. Cancer Inst. 2005, 97(17):1254-1261. 10.1093/jnci/dji249.
31. Knight W.A., Livingston R.B., Gregory E.J., McGuire W.L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977, 37(12):4669-4671.